BAVARIAN NORDIC A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 148.8 DKK | +3.26% |
|
+1.02% | -16.12% |
| 03-13 | Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults | MT |
| 03-13 | Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland | CI |
Evolution of the average Target Price on Bavarian Nordic A/S
Price target over the last 5 years
History of analyst recommendation changes
5a3d534e4fbfd41487dc176b6c6fe.3Eos5eydIV3bfVZe9cE5F7FGvUu8oNnFgW0k5S98c1w.siNzk63_TRSrJxoPmLhJQNUniz3j85iNtzxNp1cdGB-7fRqmpPJCJK83MQ~e12ff442a93c3baa3d7a78c75fbafc3f
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
148.8
DKK
Average target price
264.8
DKK
Spread / Average Target
+77.90%
High Price Target
345
DKK
Spread / Highest target
+131.78%
Low Price Target
170
DKK
Spread / Lowest Target
+14.21%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
B
EPS Revisions
- Stock Market
- Equities
- BAVA Stock
- Consensus Bavarian Nordic A/S
